LifeSpan BioSciences adds Pfizer to list of DrugTarget Database subscribers

By Angela McDaniels

Seattle, Dec. 21 - LifeSpan BioSciences Inc. said it has formed a multi-year agreement with Pfizer Inc., under which Pfizer will gain access to LifeSpan's DrugTarget Database.

The database includes informatics on more than 3200 genes, 852 comprehensive immunohistochemistry reports, localization information on more than 400 potential drug targets selected by pharmaceutical company subscribers and search and sort tools, the company said.

LifeSpan said it aims to create a comprehensive human tissue localization resource for all therapeutically important proteins. With current subscribers, the company expects to add over 200 targets to the database.

Subscribers to the DrugTarget Database can nominate targets they feel may be of therapeutic relevance. Under the agreement, Pfizer will nominate at least 60 new targets to be studied and published. For each protein studied, LifeSpan will provide immunohistochemistry localization information in 75 human normal and diseased tissues at the cellular level, often using custom generated antibodies.

The database is based on LifeSpan's GPCR and NHR family databases and has been expanded to include detailed antibody validation reports, the use of alternative confirmatory methods and more data mining tools.

LifeSpan BioSciences is a privately held company in Seattle that employs molecular pathology, bioinformatics and automated imaging systems to identify and validate targets for its biotechnology and pharmaceutical company customers.

Pfizer develops prescription medicines for humans and animals and is based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.